

### **In the Specification**

On page 1, please amend the previously submitted amendment as follows:

#### **CROSS-REFERENCE TO RELATED APPLICATIONS**

This application is ~~filed~~ a National Stage Entry under the provisions of 35 U.S.C. §371 and ~~claims the priority of~~ International Patent Application No. PCT/US2005/009325 filed on March 22, 2005, which in turn claims priority of U.S. Provisional Application No. 60/555,551 filed on March 23, 2004; and is a Continuation-in-Part of co-pending U.S. Application No. 11/144,093 filed on June 3, 2005 titled “IMMUNOREGULATORY COMPOUNDS AND DERIVATIVES AND METHODS OF TREATING DISEASES THEREWITH” issued on October 10, 2006 as US Patent No. 7, 119,119, which is a continuation of Application No 10/444,668, filed on May 23, 2003, now U.S. Patent No. 6,903,082, which is a divisional of Application No 09/942,464, filed on August 29, 2001 now U.S. Patent No: 6,583,128.